Protocol Ledger

NCT03573882 · Phase III · TERMINATED

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

Interventional Phase III clinical trial protocol NCT03573882 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-06 Enrollment: 179 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03573882
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)179 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03573882
Protocol FieldVerified Registry Value
NCT IdentifierNCT03573882
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment179 participants (ACTUAL)
Registered Start Date2018-06-06
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI